Searched over 200M research papers
2 papers analyzed
These studies suggest Renitec and Narapril are brand names for enalapril.
20 papers analyzed
Enalapril is a widely used medication for treating high blood pressure and heart failure. It belongs to a class of drugs known as ACE inhibitors, which work by relaxing blood vessels and reducing the workload on the heart. The active metabolite of enalapril, enalaprilat, inhibits the angiotensin-converting enzyme (ACE), leading to decreased levels of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure.
A study conducted to evaluate the bioequivalence of two brands of enalapril 20 mg tablets, Narapril (Julphar, UAE) and Renitec (MSD, Netherlands), demonstrated that both brands are bioequivalent. The study involved 24 healthy human volunteers in a randomized crossover design. Key pharmacokinetic parameters such as AUC (Area Under the Curve), Cmax (maximum concentration), Tmax (time to reach Cmax), T1/2 (half-life), and the elimination rate constant were measured and compared. The results showed no significant differences between the two formulations, and the 90% confidence intervals fell within the acceptable range for bioequivalence.
Another study focused on the in vitro quality evaluation of two different marketed brands of enalapril maleate tablets. This study assessed various parameters including weight variation, hardness, friability, disintegration time, and dissolution. Both brands passed all the tests according to pharmacopoeial standards, indicating that they contain equal quantities of the active pharmaceutical ingredient (API) and exhibit similar efficacy. The dissolution test, performed at pH 6.8, further confirmed that both brands have comparable dissolution profiles.
Both Narapril and Renitec have been shown to be bioequivalent, meaning they have similar pharmacokinetic profiles and therapeutic effects. Additionally, in vitro tests confirm that different marketed brands of enalapril maleate tablets meet the required quality standards and contain equal amounts of the active ingredient. Therefore, patients can expect similar efficacy and safety profiles from these brands, regardless of cost differences .
Most relevant research papers on this topic